Nila Jamal Enterprise Pharmaceutical Import Profile — Malaysia (DGFT 2022–2026)

Name: Nila Jamal Enterprise Pharmaceutical Import Records from India — 3 Products, $375.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Nila Jamal Enterprise — Pharmaceutical Importer Profile (2026) | 3 Products, $375.7K Trade | TransData Nexus

Nila Jamal Enterprise

Pharmaceutical Importer · Malaysia · Advanced Oncology Focus · $375.7K Total Trade · DGFT Verified

Nila Jamal Enterprise is a pharmaceutical importer based in Malaysia with a total trade value of $375.7K across 3 products in 3 therapeutic categories. Based on 88 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Nila Jamal Enterprise sources from 4 verified Indian suppliers, with Baba Agencies accounting for 98.9% of imports.

Nila Jamal Enterprise — Import Portfolio & Supplier Network

Nila Jamal Enterprise import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Nila Jamal Enterprise?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Baba Agencies	$16.1M	5,412	98.9%
Raghavendra Medicals	$75.0K	290	0.5%
Parisal Pharmacy	$56.6K	193	0.3%

What Formulations Does Nila Jamal Enterprise Import?

Formulation	Value	Ships
Cytolog TAB 4s (misoprostol tablets IP)	$606.7K	20
Isotroin 10MG CAPS (isotertinoin	$585.4K	18
Intacoxia 120MG TAB 10s (etoricoxib	$564.2K	28
Typbar 2.5ML (typhoid polysaccharide	$494.4K	26
Isotroin 20MG CAPS (isotertinoin	$479.9K	15
Neurobion forte TAB 30s (tablets of	$375.7K	38
Voveran sr 100MG (diclofenac prolonged	$356.4K	13
Isotroin 20MG TAB 10s (isotretinoin CAPS	$312.1K	28
Atarax 25MG (hydroxyzine hcl tablets )	$298.3K	29
Tufacne 20MG CAPS (isotertinoin	$294.7K	12
Typbar injection (typhoid	$288.3K	12
Nucoxia 120MG TAB 10s (etoricoxib	$274.6K	26
Candiforce 200MG CAPS (itraconazole CAPS	$214.8K	13
Tufacane 10MG 10s (tufacane 10MG 10s)	$212.2K	6
Amoxyclav duo syrup (amoxycillin &	$209.6K	18

Nila Jamal Enterprise imports 2,928 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tofacitinib	Advanced Oncology	$163.4K	14	4.1%	4
2	Extract	Ayurvedic & Herbal Products	$147.5K	54	1.2%	16
3	Niacin	Lipid & Metabolism	$64.7K	20	1.7%	9

Nila Jamal Enterprise imports 3 pharmaceutical products across 3 categories into Malaysia totaling $375.7K.

Nila Jamal Enterprise — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Nila Jamal Enterprise is a Malaysian pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established under the registration number 001850339-T, the company operates from its headquarters at No. 8 Jalan Cheng Perdana 1/23, Taman Cheng Perdana, 75250 Melaka, Malaysia. While specific details about its parent company are not publicly available, Nila Jamal Enterprise plays a significant role in Malaysia's pharmaceutical distribution network by sourcing a diverse range of pharmaceutical products from international suppliers, particularly from India.

2Distribution Network

The company maintains a centralized distribution model, with its primary warehouse located in Melaka, Malaysia. This strategic location facilitates efficient logistics and distribution across the country. While there is no publicly available information regarding additional warehouse locations or logistics capabilities, Nila Jamal Enterprise's extensive import activities suggest a well-established infrastructure capable of handling a substantial volume of pharmaceutical products.

3Industry Role

Nila Jamal Enterprise functions as a primary wholesaler in Malaysia's pharmaceutical supply chain. By importing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a steady supply of various pharmaceutical products to meet the demands of the Malaysian market. Its role is crucial in bridging the gap between international manufacturers and local healthcare providers, thereby contributing to the accessibility of essential medications within Malaysia.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Nila Jamal Enterprise

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a limited number of suppliers. Notably, BABA AGENCIES accounts for approximately 98.9% of the total import value, indicating a dominant supplier relationship. This concentrated sourcing approach may present risks, such as supply chain disruptions if issues arise with the primary supplier. However, the stability of this relationship, as evidenced by the consistent volume of shipments, suggests a strategic choice aimed at ensuring product consistency and reliability.

2Supply Chain Resilience

Nila Jamal Enterprise's supply chain resilience appears to be heavily reliant on its primary supplier, BABA AGENCIES. The lack of publicly available information regarding backup suppliers or alternative sourcing strategies indicates potential vulnerabilities in the event of disruptions. The company's focus on a single supplier may limit its ability to adapt to changes in the supply chain, such as regulatory shifts or logistical challenges. Additionally, the absence of data on the regulatory compliance of key suppliers raises questions about the robustness of the supply chain's adherence to international standards.

Strategic Implications

Importing Pharmaceuticals into Malaysia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Malaysia

1Regulatory Authority & Framework

In Malaysia, the importation and distribution of pharmaceutical products are regulated by the National Pharmaceutical Regulatory Agency (NPRA), operating under the Ministry of Health Malaysia (MOH). The primary legislation governing these activities includes the Control of Drugs and Cosmetics Regulations 1984, the Sale of Drugs Act 1952, and the Poisons Act 1952. These regulations establish the standards for the manufacture, import, export, and distribution of drugs and medical devices in Malaysia. The Drug Control Authority (DCA) within the NPRA is responsible for evaluating and approving pharmaceutical products for sale and use in Malaysia, ensuring their safety, efficacy, and quality. (npra.gov.my)

2Import Licensing & GMP

Importers of pharmaceutical products in Malaysia are required to obtain an Import License issued by the Director of Pharmaceutical Services under Regulation 12(1)(d) of the Control of Drugs and Cosmetics Regulations 1984. This license authorizes the importation and wholesale distribution of registered products. Additionally, importers must comply with Good Manufacturing Practice (GMP) standards, which are mandatory for manufacturers and importers to ensure the quality and safety of pharmaceutical products. The NPRA provides guidelines on the application process for these licenses, emphasizing the need for compliance with GMP and Good Distribution Practice (GDP) standards. (npra.gov.my)

Nila Jamal Enterprise — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Nila Jamal Enterprise's focus on importing products in the Advanced Oncology, Ayurvedic & Herbal Products, and Lipid & Metabolism therapeutic categories aligns with the growing demand for specialized and alternative treatments in Malaysia. The substantial import value in these categories indicates a strategic approach to meet the evolving healthcare needs of the Malaysian population. The company's product mix suggests an understanding of market trends and a commitment to providing a diverse range of therapeutic options to healthcare providers and patients.

2Sourcing Profile

Nila Jamal Enterprise's sourcing strategy is heavily centered on generic drugs, with a significant emphasis on formulations imported from India. This approach allows the company to offer cost-effective pharmaceutical products while maintaining a diverse portfolio across various therapeutic categories. The reliance on Indian suppliers, particularly BABA AGENCIES, underscores the importance of establishing strong supplier relationships to ensure a consistent and reliable supply chain.

3Market Positioning

Based on its product mix, Nila Jamal Enterprise serves a broad segment of the Malaysian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's diverse product offerings cater to various therapeutic needs, positioning it as a comprehensive wholesaler capable of supplying a wide range of pharmaceutical products to different healthcare providers.

Seller's Guide — How to Become a Supplier to Nila Jamal Enterprise

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to establish relationships with Nila Jamal Enterprise, given the company's significant import volume and reliance on Indian products. Potential gaps in the company's current sourcing include the need for alternative suppliers to mitigate risks associated with supplier concentration and to enhance supply chain resilience. New suppliers can offer competitive pricing, product diversity, and reliability to meet the company's requirements.

2Requirements & Qualifications

Indian exporters seeking to supply Nila Jamal Enterprise must ensure that their products are registered with the Drug Control Authority (DCA) in Malaysia and comply with the Control of Drugs and Cosmetics Regulations 1984. Additionally, exporters must hold the appropriate licenses, including an Import License and a Wholesale Dealer's License, as issued by the NPRA. Compliance with GMP and GDP standards is mandatory to ensure product quality and safety. (npra.gov.my)

3How to Approach

Frequently Asked Questions — Nila Jamal Enterprise

What products does Nila Jamal Enterprise import from India?

Nila Jamal Enterprise imports 3 pharmaceutical products across 3 categories. Top imports: Tofacitinib ($163.4K), Extract ($147.5K), Niacin ($64.7K).

Who supplies pharmaceuticals to Nila Jamal Enterprise from India?

Nila Jamal Enterprise sources from 4 verified Indian suppliers. The primary supplier is Baba Agencies (98.9% of imports, $16.1M).

What is Nila Jamal Enterprise's total pharmaceutical import value?

Nila Jamal Enterprise's total pharmaceutical import value from India is $375.7K, based on 88 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Nila Jamal Enterprise focus on?

Nila Jamal Enterprise imports across 3 categories. The largest: Advanced Oncology (43.5%), Ayurvedic & Herbal Products (39.3%), Lipid & Metabolism (17.2%).

Get Full Nila Jamal Enterprise Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.